Singapura - Inggris - HSA (Health Sciences Authority)

pharmed import & export pte ltd - ear, nose & throat - marimer isotonic is recommended for daily hygiene of the nasal airways, for the humidification of the dried nasal mucosal membrane and as a complement to the treatment of ent disorders

Singapura - Inggris - HSA (Health Sciences Authority)

hcp healthcare asia pte. ltd. - general hospital - urgostart contact is indicated for covering and treating the following skin wounds: - leg ulcers - diabetic foot ulcers - pressure ulcers (bedsores) - other long-lasting or recurrent wounds or wounds at risk of long lasting it is also suitable for application to wounds with difficult skin localisation, or to hollow cavity or deep wounds. it can also be packed in deep wounds. it is intended for use on wounds mainly covered with granulation tissue (red tissue in the wound).

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratoire glaxosmithkline - lamotrigina - lamotrigina....25,000 mg

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratoire glaxosmithkline - lamotrigina - lamotrigina....50.00 mg

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 100ug;  ;   - powder for inhalation - 100 mcg - active: fluticasone propionate 100ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug;  ;   - powder for inhalation - 250 mcg - active: fluticasone propionate 250ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 50ug;  ;   - powder for inhalation - 50 mcg - active: fluticasone propionate 50ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 500ug;  ;   - powder for inhalation - 500 mcg - active: fluticasone propionate 500ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 100ug (micronised);  ;  ;  ; salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base;  ;  ;   - powder for inhalation - 100µg/50µg - active: fluticasone propionate 100ug (micronised)       salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base       excipient: lactose monohydrate - seretide is indicated for the regular treatment of asthma (reversible obstructive airways disease), where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of both long-acting beta-agonists and inhaled corticosteroids using separate therapy. patients who are not adequately controlled on current inhaled corticosteroid therapy. patients who are not adequately controlled on 'as needed' short-acting beta-agonistsm as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroids alone. seretide should not typically be used for the initial management of asthma, unless symptoms are severely uncontrolled, nor in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists. seretide should not be used in the treatment of acute asthmatic symptoms.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug (micronised);  ;  ;  ; salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base;  ;  ;   - powder for inhalation - 250µg/50µg - active: fluticasone propionate 250ug (micronised)       salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base       excipient: lactose monohydrate - seretide is indicated for the regular treatment of asthma (reversible obstructive airways disease), where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of both long-acting beta-agonists and inhaled corticosteroids using separate therapy. patients who are not adequately controlled on current inhaled corticosteroid therapy. patients who are not adequately controlled on 'as needed' short-acting beta-agonistsm as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroids alone. seretide should not typically be used for the initial management of asthma, unless symptoms are severely uncontrolled, nor in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists. seretide should not be used in the treatment of acute asthmatic symptoms.